Venture Capital for Deep-Tech and HealthTech Technologies
Investment in deep-tech, healthtech
and life science is an investment for the future
Our Mission
Providing investment opportunities in early and mid-stage deep-tech and healthtech technology companies that develop innovative products and services that save/improve lives
Our Investment Focus
Digital Health
Healthcare AI
Medical Devices & Robotics
Advanced Innovative Technologies
Deep-Tech
Cyber Security
Advantages
Why Peaks Health
A vehicle for investments in deep-tech and healthtech technologies, providing projects a funding platform
Extensive Network
Access to identify top healthcare technologies
Robust Ecosystem
Support with critical strategic partners and hands-on management
Excellent Team
An experienced leadership with proven track records
Healthcare Focus
We specialize exclusively in healthcare technologies
Participation in Peaks incubation program provides to early-stage startups with support from best experts in the industry
Peaks Health offers a full support: starting with a project “package” and up to the stage of entering the market
Our Team
Founders and Management Team
CEO and Managing partner at Compass Ventures Group and former President of the Advertising & Media division at Amdocs and senior manager in many leading multinational companies, he is an experienced international executive manager and investor with an impressive track record in technology companies, specializing in fund management and leading global investment projects in technology and innovation. His expertise includes sourcing cutting-edge technology products and solution in a range of sectors, and bringing them to market, with a focus on international markets.
Moshe Kamar
CEO of Peaks Ventures & former Co-Founder & CEO of AIT and BioMimic Pharma; both have been acquired by US companies. She has worked for leading Israeli biotech companies and has been involved in establishing a number of start-up companies. She has served as an advisor for investors and accelerators in the life science field in Israel.
Mira Peled Kamar
CEO of EverFlow and a Blockchain serial entrepreneur with extensive experience in the start-up sphere. Over 15 years of executive role at tech companies, with a broad network of contacts in various vertical markets globally. An early stage investor in various ventures in the fintech market.
Sharon Greenberg
CEO and Managing partner at Compass Ventures Group and former President of the Advertising & Media division at Amdocs and senior manager in various leading multinational companies, he is an experienced international executive manager and investor with an impressive track record in technology companies, specializing in fund management and leading global investment projects in technology and innovation. His expertise includes sourcing cutting-edge technology products and solutions in a range of sectors, and bringing them to market, with a focus on international markets.
Operational Experience
- CEO and Managing Partner of Compass Ventures Group
- Board member in several of Compass ventures subsidiaries
- Held several senior management positions at Amdocs, the last of which was President of the Advertising, Media and Entertainment Division.
Moshe Kamar
Managing partner, Chairman & CEO
Founder and CEO of Peaks Ventures with over 30 years’ management experience in the biotech industry; scientific development and building business strategies.
Served as the Head of Life Science in Compass Ventures Group, as well as co-founding and CEO of AIT and BioMimic Pharma, two prominent cancer immunotherapy companies that were acquired by US companies. She has also worked with the first leading Israeli biotech companies; Biotechnology General and Interpharm.
Earned her PhD in Biochemistry and Molecular Biology from the Weizmann Institute of Science and completed her post-doctorate at the University of California, Berkeley.
Mira Peled
Managing partner, President
CEO of EverFlow and a Blockchain serial entrepreneur with extensive experience in the start-up sphere.
Over 15 years of executive roles at tech companies, with a broad network of contacts in several vertical markets globally.
An early stage investor in several ventures in the fintech market.
Sharon (Gigi) Greenberg
Managing partner, Head of Tech and AI
Mr. Zeev Holtzman is CEO of Giza fund with over 20 years’ experience in the Private Equity and Investment Banking sectors. At Giza Mr. Holtzman focuses on strategy, networking, deal sourcing, and the company’s activities in Asia and Poland while acting as Chairman of the GPV-Poland Investment Committee.
Zeev Holtzman
Business and Investments
Past Performance
Over
$
0
M
Invested
Over
0
Investments
Over
0
exits
with total value about $8B
High IRR
Over
$
0
M
Invested
Over
0
Investments
Over
0
exits
with total value overt $8B
High IRR
Strategic Partners
Fund Advantages
» Strong, experienced and hands-on management team
» Access to disruptive deep-tech and healthtech technologies creates a unique deal-flow
» Wide network with academic institutions, industry leaders, experts
» Collaborations with Israeli leading hospitals
» Existing attractive deal flow for investment
Companies Seeking Capital
At Peaks Health, our experienced team is dedicated to discovering and researching a multitude of cutting-edge technological opportunities
An innovative immunotherapy company
Cancer is a major cause of death worldwide. There is a huge unmet need for novel cancer therapies, but the greatest challenge is the lack of good targets.
Cancer cells shield themselves with sugar-coating to evade the immune system. Cell surface glycans have different abnormal structures that are not found in healthy cells. So the cancer cell sugar-coat is actually different, generating carbohydrate-neoantigens (cAg) that are excellent targets for cancer therapy.
Glyconia developed an innovative technology targeting cAgs on cancer cells with engineered CAR-T, turning them into cancer-killing machines for optimal efficacy, particularly in solid tumors.
Body mole mapping and tracking system
Marpé Technologies is a science based company developing innovative scanners for early detection of skin cancer.
Prototype scanners are operating at the Tel Aviv Sourasky Medical Center and the Bnei Zion Medical Center in Haifa, both leading hospitals in Israel, indicating the superior features of Marpe’s technology.
Detecting early vital
warning signs
ATLASense Platform is the only personalized, continuous, and comprehensive health surveillance system to assist in the prevention of deterioration by detecting unique early warning signs both in-hospital and at home.
Portable home dialysis - only 20 minutes each session
Patients can dialyze from home, work, or while on vacation while going about their regular lives thanks to iRen portable iDA devices and still being remotely monitored to personalize the therapy. The dialysis provided by iRen technology is safe, simple to use, and affordable. It takes 20 minutes, 3 sessions a day.
An innovative immunotherapy company
Cancer is a major cause of death worldwide. There is a huge unmet need for novel cancer therapies, but the greatest challenge is the lack of good targets.
Cancer cells shield themselves with sugar-coating to evade the immune system. Cell surface glycans have different abnormal structures that are not found in healthy cells. So the cancer cell sugar-coat is actually different, generating carbohydrate-neoantigens (cAg) that are excellent targets for cancer therapy.
Glyconia developed an innovative technology targeting cAgs on cancer cells with engineered CAR-T, turning them into cancer-killing machines for optimal efficacy, particularly in solid tumors.
Body mole mapping and tracking system
Marpé Technologies is a science based company developing innovative scanners for early detection of skin cancer.
Prototype scanners are operating at the Tel Aviv Sourasky Medical Center and the Bnei Zion Medical Center in Haifa, both leading hospitals in Israel, indicating the superior features of Marpe’s technology.
Detecting early vital
warning signs
ATLASense Platform is the only personalized, continuous, and comprehensive health surveillance system to assist in the prevention of deterioration by detecting unique early warning signs both in-hospital and at home.
Transforming Breast Cancer Care With AI Agents
MEDow.AI is Transforming Breast Cancer Care With AI Agents. With our Patient-Centered Conversational AI Platform, Clinics gain a centralized dashboard to monitor patient health, flag urgent needs, and deploy proactive workflows and their patients receive a 24/7 personalized AI companion.
Nevia
Nevia bio is a developing a machine learning based platform of early detection in women’s health space, using an untapped biofluid- vaginal secretions. The Nevia platform is designed to decode data from biofluids, and to gain insights about physiological conditions, presenting promising clinical results in its first indication: ovarian cancer.
More investment opportunities
Want to see more exclusive, carefully selected investment opportunities?
Register now to get full access to our exclusive list here